* * 100033 * 2015 KT201512 87
2017 1 WHO 2004 2013 4. 2 7. 3 6. 5% 1 2 2015 12 54 1 http / /www. who. int /gho /en 2015-06 - 30 2 7 88
71% 80% 2012 2 500 HIV /AIDS 70% 160 120 2014 15 ~ 24 1. 2% 3. 8% 1. 1% 2013 900 150 240 50 1 2013 1. 98 2 80% 58. 4 90% 2010 1 200 25 2 000 3 2030 21% 46% 2008 28% 4 2011 27 2030 1 2 3 4 Http / /www. who. int /gho /malaria /en 2015-05 - 15. Http / /apps. who. int /gho /data /node. main. A1372 lang = en 2015-06 - 30. Http / /www. diabetes. co. uk /global - diabetes /diabetes - in - africa. html 2015-06 - 30. Http / /www /bioon. com /industry /internation /534163. shtml 2015-06 - 30. 89
2017 1 61% 1 15 2000 284 2012 1 170 Compound Annual Growth Rate 12. 5% 42 199 9% 41 112 2 2063 75 2013 9 900 200 2% 1 110 1 /3 40 1% 54 1 000 9 000 130 1 2 Http / /africa - health. com /articles /may_ 2013 /Diabetes. pdf 2015-06 - 30. Http / /www. who. int /gho /malaria /en 2015-05 - 15. 90
20% ~ 30% 1 1 2013 http / /www. unaids. org 60% 47 70% 1 AfDB Revitalizing Africa s Pharmaceutical Industry http / /www. afdb. org /en /news - and - events /article /revitalizing - africas - pharmaceutical - industry - 13289 2015-06 - 15. 91
2017 1 Medis Aspen Quality Chemical GMP 1 2007 54 2012 7 EAC 2011 44 200 66 12. 5% 2. 5% 1 Africa Union Pharmaceutical Manufacturing Plan for Africa PMPA - Business Plan 2012 http / /apps. who. int /medicinedocs /documents /s20186en /s20186en. pdf 2015-06 - 30. 92
10% 2. 5% 20% 5% 30% 70% FMHACA FBPIDI 80% 21 20 50 60 20 90 1996 SPC CMS - SSPC 93
2017 1 5 6 6 6 1-1996 55% 45% 20 000 350 100 3 2 / 1997 2 1 25 2012 2 000 GMP 1999 13. 75 60 1 1 500 PVC 2 2008 5 5 000 3 3 94
370 62% 2009 103 2. 5 4 000 3 000 95
2017 1 5-96
1 17 2 1 2013 http / /www. chyxx. com /industry / 201212 /191506. html 2015-06 - 30 2 17 97
2017 1 1 50 48 2014 50 16 9 5 1 2011 164 98
3 2 2 2 50 http / /www. pharmexec. com 99
2017 1 5 000 15 000 60 4 500 10 10% 20% 30% 7% ~ 8% 5 15% 12 CTD 1 1 100 Common Technical Document CTD
2013 30 FDA ANDA 10 10% 101
2017 1 54 102
3 70% - 20% 10% ~ 40% 10% 103
2017 1 PQ 1 1 80% 2014 6 497 14 70% PQ 104
GAVI 1 1 The Global Alliance for Vaccines and Immunization GAVI 1999 105
2017 1 TRIPs WTO AMRHP 106
2016 ECOWAS 107
2017 1 108
1 1 109
2017 1 110
50 111
2017 1 China s Participation in Public Health Governance in Africa A Perspective of Cooperation in Pharmaceutical Investment Chi Jianxin Abstract China - Africa Public Health Cooperation Program is one of the Ten Cooperation Programs advocated in the Johannesburg Summit of FOCAC. Pharmaceutical cooperation especially investment cooperation is the key point of the implementation of public health cooperation plan for both China and Africa. Africa s current health system is weak and the supply - demand imbalance in the medicine market is serious while the pharmaceutical industry in Africa has great potential. Chinese enterprises have both opportunities and challenges when entering Africa s pharmaceutical market. Chinese investment in African pharmaceutical market is challenged by industrial upgrading and market competition and the investment scale is generally small. The enterprises mainly focus on production and do not pay equal efforts on circulating which leads to a shortfall in the capacity of international market development. The Going - Global strategy for Chinese pharmaceutical enterprises needs further systematic policy support. In the following years China should catch the opportunity window of pharmaceutical cooperation between China and Africa improve market research and planning capacity upgrade investment cooperation strengthen financial support combine investment with aid in the pharmaceutical sector and enhance the investment capacity of Chinese enterprises. China should also strive to make mutual recognition of China s and Africa s medicine standard and explore the possibilities of developing key African countries into African pharmacy. Key Words Public Health Governance China - Africa Cooperation Investment in Pharmaceutical Sector African Pharmacy 112